In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Trial Results

Related Pages

Breast Cancer Trial Results

Trastuzumab Benefits Women with Locally Advanced or Inflammatory Breast Cancer
(Posted: 03/15/2010, Updated: 04/07/2014) - Women treated with trastuzumab (Herceptin) and chemotherapy before surgery and trastuzumab again after surgery had a reduced risk of the disease recurring or progressing compared with women who received pre-surgical chemotherapy but no trastuzumab, according to a study published in the January 30, 2010, Lancet.

Two Drugs that Hit One Target Show Efficacy against Metastatic Breast Cancer
(Updated: 04/30/2013) - Combining two drugs that target the HER2 protein, trastuzumab (Herceptin®) and pertuzumab, with chemotherapy is a new treatment option for women with HER2-positive metastatic breast cancer, according to results from a large clinical trial.

Women with Breast Cancer Micrometastases in Their Sentinel Lymph Nodes May Not Need Axillary Dissection
(Posted: 04/26/2013) - Results from a randomized clinical trial showed that women with breast cancer and only micrometastases in their sentinel lymph nodes who received axillary lymph node dissection had more side effects but no improvement in disease-free survival compared with women who had no further lymph node surgery.

Ten Years of Tamoxifen Reduces Breast Cancer Recurrences, Improves Survival
(Posted: 03/20/2013) - Taking adjuvant tamoxifen for 10 years after primary treatment leads to a greater reduction in breast cancer recurrences and deaths than taking the drug for only 5 years, according to the results of a large international clinical trial.

For Some Breast Cancers, New Drug May Be Treatment Option
(Posted: 06/13/2012, Updated: 11/29/2012) - Results from an international clinical trial suggest that women with metastatic, HER2-positive breast cancer that is no longer responding to the targeted therapy trastuzumab (Herceptin) may soon have a new treatment option. Women who received the investigational drug trastuzumab emtansine (T-DM1) lived more than 3 months longer without their tumors progressing than women who received the chemotherapy drug capecitabine (Xeloda) and the targeted drug lapatinib (Tykerb).

1 2 3 4 5 6 7 8 9  Next >